Literature DB >> 27966805

Successful treatment of mature B-cell lymphoma with rituximab-based chemotherapy in a patient with Bloom syndrome.

Wasil Jastaniah1,2.   

Abstract

This report presents a case of Bloom syndrome (BS) in a consanguineous Saudi family. The patient, an 11-year-old male with mature B-cell lymphoma, had minimal therapeutic response and significant dose-limiting toxicity with standard chemotherapy treatment. He later responded successfully to a rituximab-based chemotherapy protocol. This case highlights that the rituximab-based chemotherapy protocol is an effective and safe treatment alternative for mature B-cell lymphoma in patients with BS. Further trials are warranted to investigate this modality of treatment.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  B-cell lymphoma; Bloom syndrome; chemotherapy; rituximab

Mesh:

Substances:

Year:  2016        PMID: 27966805     DOI: 10.1002/pbc.26385

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

1.  Diagnosis of Bloom Syndrome in a Patient with Short Stature, Recurrence of Malignant Lymphoma, and Consanguineous Origin.

Authors:  Jakub Trizuljak; Terezie Petruchová; Ivona Blaháková; Zuzana Vrzalová; Věra Hořínová; Martina Doubková; Jozef Michalka; Jiří Mayer; Šárka Pospíšilová; Michael Doubek
Journal:  Mol Syndromol       Date:  2020-03-21

2.  Multidisciplinary management of endocrinopathies and treatment-related toxicities in patients with Bloom syndrome and cancer.

Authors:  Carolyn Fein Levy; Lubaina S Presswala; Alana Slomovic; Jessica Stiefel; Rifka Schulman-Rosenbaum
Journal:  Pediatr Blood Cancer       Date:  2020-11-23       Impact factor: 3.838

Review 3.  Current Understanding and Future Research Priorities in Malignancy Associated With Inborn Errors of Immunity and DNA Repair Disorders: The Perspective of an Interdisciplinary Working Group.

Authors:  Simon Bomken; Jutte van der Werff Ten Bosch; Andishe Attarbaschi; Chris M Bacon; Arndt Borkhardt; Kaan Boztug; Ute Fischer; Fabian Hauck; Roland P Kuiper; Tim Lammens; Jan Loeffen; Bénédicte Neven; Qiang Pan-Hammarström; Isabella Quinti; Markus G Seidel; Klaus Warnatz; Claudia Wehr; Arjan C Lankester; Andrew R Gennery
Journal:  Front Immunol       Date:  2018-12-12       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.